Vol. 2 No. 7 (2022)
Reimbursement Recommendations

Cenegermin (Oxervate)

Published July 12, 2022

Key Messages

  • CADTH recommends that Oxervate be reimbursed by public drug plans for the treatment of moderate to severe neurotrophic keratitis (NK) in adult patients if certain conditions are met.
  • Oxervate should only be covered to treat patients who have never been treated with Oxervate before and have previously tried but failed conventional nonsurgical therapies.
  • Oxervate should only be reimbursed if prescribed by a cornea specialist experienced in the management of NK or by an ophthalmologist when comanaging the patient with a cornea specialist. Oxervate should not be prescribed along with preservative-containing topical antibiotics and/or antiviral eye drops. The cost of Oxervate should be reduced.